Skip to main content

Advertisement

SpringerLink
Log in

Do reductions in risk of cardiorenal events with SGLT2 inhibitors in type 2 diabetes vary with baseline characteristics? A meta-analysis

  • Research Letter
  • Published:
Endocrine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. S.D. Wiviott, I. Raz, M.P. Bonaca et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 380(4), 347–357 (2019)

    Article  CAS  Google Scholar 

  2. B. Neal, V. Perkovic, K.W. Mahaffey et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377(7), 644–657 (2017)

    Article  CAS  Google Scholar 

  3. B. Zinman, C. Wanner, J.M. Lachin et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373(22), 2117–2128 (2015)

    Article  CAS  Google Scholar 

  4. V. Perkovic, M.J. Jardine, B. Neal et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380(24), 2295–2306 (2019)

    Article  CAS  Google Scholar 

  5. D. Fitchett, B. Zinman, C. Wanner et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the empa-reg outcome(r) trial. Eur. Heart J. 37(19), 1526–1534 (2016)

    Article  CAS  Google Scholar 

  6. C. Wanner, S.E. Inzucchi, J.M. Lachin et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. 375(4), 323–334 (2016)

    Article  CAS  Google Scholar 

  7. K. Radholm, G. Figtree, V. Perkovic et al. Canagliflozin and heart failure in type 2 diabetes mellitus. Circulation 138(5), 458–468 (2018)

    Article  CAS  Google Scholar 

  8. V. Perkovic, D. de Zeeuw, K.W. Mahaffey et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the canvas program randomised clinical trials. Lancet Diabetes Endocrinol. 6(9), 691–704 (2018)

    Article  CAS  Google Scholar 

  9. O. Mosenzon, S.D. Wiviott, A. Cahn et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the declare-timi 58 randomised trial. Lancet Diabetes Endocrinol. 7(8), 606–617 (2019)

    Article  CAS  Google Scholar 

  10. K.W. Mahaffey, M.J. Jardine, S. Bompoint et al. Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups. Circulation 140(9), 739–750 (2019)

    Article  CAS  Google Scholar 

  11. C.P. Cannon, V. Perkovic, R. Agarwal et al. Evaluating the effects of canagliflozin on cardiovascular and renal events in patients with type 2 diabetes mellitus and chronic kidney disease according to baseline hba1c, including those with hba1c <7%: results from the credence trial. Circulation 141(5), 407–410 (2020)

    Article  Google Scholar 

  12. J. McMurray, S.D. Solomon, S.E. Inzucchi et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 381(21), 1995–2008 (2019)

    Article  CAS  Google Scholar 

  13. T.A. Zelniker, S.D. Wiviott, I. Raz et al. Sglt2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393(10166), 31–39 (2019)

    Article  CAS  Google Scholar 

  14. B.L. Neuen, T. Young, H. Heerspink et al. Sglt2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol, 7(11), 845–854 (2019)

    Article  CAS  Google Scholar 

  15. C. Arnott, Q. Li, A. Kang et al. Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J. Am. Heart Assoc. 9(3), e14908 (2020)

    Article  Google Scholar 

  16. T. Toyama, B.L. Neuen, M. Jun et al. Effect of sglt2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis. Diabetes. Obes. Metab. 21(5), 1237–1250 (2019)

    Article  CAS  Google Scholar 

  17. S.E. Inzucchi, D. Fitchett, D. Jurišić-Eržen et al. Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy? Diabetes Obes. Metab. 22(4), 631–639 (2020)

    Article  CAS  Google Scholar 

  18. T. Ohkuma, L. Van Gaal, W. Shaw et al. Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the canvas program. Diabetes Obes. Metab. 22(4), 530–539 (2020)

    Article  CAS  Google Scholar 

  19. J.B. Buse, D.J. Wexler, A. Tsapas et al. 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the american diabetes association (ada) and the european association for the study of diabetes (easd). Diabetes Care 43(2), 487–493 (2020)

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of General Medicine, Guangdong Medical University Affiliated Longhua Central Hospital, Shenzhen, China

    Mei Qiu

  2. Department of Endocrinology, Second Affiliated Hospital of Kunming Medical University, Kunming, China

    Shu-Yan Liu

  3. Department of Cardiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China

    Jin-Song Gu

  4. Department of General Medicine, The Central Hospital of Tuoshi Town, Tianmen, China

    Kai-Kai Li

  5. Department of Nephrology, First Affiliated Hospital of Kunming Medical University, Kunming, China

    Ling-Lin Li

  6. Department of Endocrinology, Guangdong Medical University Affiliated Longhua Central Hospital, Shenzhen, China

    Liang-Liang Ding

Authors
  1. Mei Qiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shu-Yan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jin-Song Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kai-Kai Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ling-Lin Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Liang-Liang Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Liang-Liang Ding.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Qiu, M., Liu, SY., Gu, JS. et al. Do reductions in risk of cardiorenal events with SGLT2 inhibitors in type 2 diabetes vary with baseline characteristics? A meta-analysis. Endocrine 69, 688–691 (2020). https://doi.org/10.1007/s12020-020-02359-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-020-02359-5

Search

Navigation